Morpholino (PMO)
An uncharged oligo analogue that blocks its target by steric hindrance rather than cutting.
A morpholino, or phosphorodiamidate morpholino oligomer, replaces the natural sugar phosphate backbone with a neutral morpholine and phosphorodiamidate structure. Because it carries no charge and is highly stable, it works by physically blocking its target rather than recruiting an enzyme.
Morpholinos are well suited to splice switching applications, including approved treatments for Duchenne muscular dystrophy.
Related terms
Design with these concepts on Syngenis One
Our platform puts the chemistry behind these terms to work, from candidate design to synthesis ready oligo.
One engine, working across the whole business.
Syngenis One (AI Discovery)
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Manufacturing
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
Research and Diagnostics
AI led therapeutic programs and an aptamer based diagnostics pipeline.
Clinical
A specialist nucleic acid CRO with in silico trial modelling.
Life Care
Consumer genomics at a mass market price.
Fund
Infrastructure that channels research investment into the pipeline.